Artivion
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 1.5K
- Market Cap
- -
- Introduction
Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction Surgery
- Conditions
- Congenital Heart DiseaseCardiac Anomaly
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Artivion Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05314868
- Locations
- 🇺🇸
Children's Hospital of Boston, Boston, Massachusetts, United States
PERSEVERE- a Trial to Evaluate AMDS in Acute DeBakey Type I Dissection
- Conditions
- Acute Aortic Dissection
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Artivion Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT05174767
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
- Conditions
- Aortic Valve DiseaseAortic Valve StenosisAortic Valve Failure
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Artivion Inc.
- Target Recruit Count
- 863
- Registration Number
- NCT04142658
- Locations
- 🇺🇸
Tucson Heart Center, Tucson, Arizona, United States
🇺🇸CHI St. Vincent Heart Institute, Little Rock, Arkansas, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery
- Conditions
- Peripheral Arterial DiseaseCarotid Artery DiseasesAbdominal Aortic AneurismVascular DiseasesHemodialysis Access Failure (Disorder)
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Artivion Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT03669042
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸Iowa Heart Center, Des Moines, Iowa, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System
- Conditions
- Blood Loss, Surgical
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Artivion Inc.
- Target Recruit Count
- 324
- Registration Number
- NCT02359994
- Locations
- 🇺🇸
Indiana University d/b/a/ Methodist Research Institute, Indianapolis, Indiana, United States
News
Artivion's AMDS Hybrid Prosthesis Receives FDA Humanitarian Device Exemption for Acute Aortic Dissections
Artivion's AMDS Hybrid Prosthesis has received FDA Humanitarian Device Exemption for treating acute DeBakey Type I aortic dissections with malperfusion.
Endospan Completes Enrollment in TRIOMPHE Trial for NEXUS Aortic Arch Stent Graft
Endospan has concluded enrollment in the primary arm of the TRIOMPHE study, evaluating the NEXUS stent graft for aortic arch disease treatment.